Proxygen

NEW GLUE HUNTER +++ We’re excited to welcome Adam Davenport as Proxygen’s new Chief Discovery Officer. With 25+ years of drug hunting experience, Adam will help drive our first-in-class pipeline of glue degraders towards clinical development! Read Adam's full background in our Chronicle: https://lnkd.in/dJrMGZpG #TheArtOfGlueHunting #Glues #TPD

Don't miss our Co-Founder & Chief Glue Hunter Georg Winter's talk at Dana-Farber Cancer Institute on November 7 at 12PM EST / 6PM CET. The TPD Webinar Series features thought leaders & trailblazers in the targeted protein degradation field and it is a great way to dive deeper into Georg's pioneering work at the forefront of glue hunting. Webinar: https://lnkd.in/eyxkVinE More about Proxygen: proxygen.com #TheArtOfGlueHunting

I will be speaking at Investival Showcase 2024, taking place on 18 November 2024 at Tobacco Dock. Join us to connect life science & healthcare executives with capital and kick off Europe's biggest dedicated healthcare investment week. #Investival https://lnkd.in/dHcjyNEp Investival Showcase

Use the opportunity to connect with us and find out more about #TheArtOfGlueHunting. Our CEO Bernd Boidol will be in Stockholm next week for the Bio-Europe conference and he can't wait to tell you more about what we do best.

Looking forward to joining the panel on “Lessons Learned from a Major Strategic Partnership Deal for a Platform” at the TPD & Induced Proximity Summit in Boston next week. Join me and trailblazers Barbara Lueckel (Global Head of Research Technologies, Roche), Scott Boyle, Ph.D. MBA (CBO, C4 Therapeutics), and Jason Kantor (CBO, Nurix Therapeutics). #TheArtOfGlueHunting Proxygen

🚨 New Website Alert 🚨 www.proxygen.com 🚨 Proxygen was founded on the belief that significant progress demands boldness and smart differentiation. Instead of aspiring to be 'like' others, we set out to explore uncharted territory, driven by the confidence that our deep scientific roots will guide us in the right direction. This mindset is imperative in a scientific field so groundbreaking and novel like targeted protein degradation. Finding #gluedegraders requires more than just the standard approaches. After all, they represent the paradigm shift in pharmacology that we’ve all been eagerly awaiting. At Proxygen, we do things differently, unconventionally. We combine the art and the skill of hunting for glue degraders. Our new website and visual identity finally reflect this spirit and align perfectly with the cunning science that has defined us from the beginning. Check it out: www.proxygen.com A special shoutout to the outstanding team at Alessandri - Design & Marken Manufaktur, led by the wonderful Cordula Alessandri. The results of your work show just how captivated you were by our story. You truly incorporate the glue hunter spirit.

Collaboration on all levels // Outstanding work by the academic labs of Proxygen co-founder and head of our Scientific Advisory Board Georg Winter and Proxygen SAB member Brenda Schulman - how great to see these two pioneers working together so productively Read the full article: https://lnkd.in/dZ48-fhW

Looking forward to participating in Wednesday's panel on "Co-opting Existing Biological Processes to Drug Cancer and Other Diseases" at the BIO International Convention in San Diego. Host Mariana Mihalusova (Venrock) has assembled a brilliant group of pioneers and thought leaders with Drs. Aetna Wun Trombley (CEO Lycia), Larry Hamann (CEO Interdict), and George Eliades (CEO Mythic). Join us for an insightful conversation on Wednesday, June 5 at 4:15 PM. See you there. #BIO2024

Absolutely stunning!! Congratulations to Proxygen co-founder & head of our Scientific Advisory Board Georg Winter and his team for using their deep scientific roots to push the limits of drug discovery once again. Chapeau!!

Next achievement unlocked +++ Congratulations to Proxygen Co-Founder & Head of our Scientific Advisory Board Georg Winter and all contributing authors for adding yet another piece to the molecular glue degrader puzzle +++